The IHC staining of tumor sections suggested that ProAgio treatment decreased Hif-1a in lung tumors (Figure 4B,C), suggesting that, similar to our observations with pancreatic and breast cancer, ProAgio treatment decreased lung cancer hypoxia due to its anti-angiogenic effects. The gene discussed is HIF1A; the disease is lung cancer.